home / stock / snpx / snpx short
Short Information | Synaptogenix Inc. (OTCMKTS:SNPX)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 576,493 |
Total Actual Volume | 965,152 |
Short Trends | |
---|---|
Cover Days | 0 |
Short Days | 14 |
No Change Days | 6 |
Averages | |
---|---|
Average Short Volume | 28,825 |
Average Short Percentage | 60.94% |
Is there a SNPX Short Squeeze or Breakout about to happen?
See the SNPX Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
05-18-2021 | $1.35 | $1.56 | $1.6 | $1.27 | 38,601 | 26,694 | 69.15% |
05-17-2021 | $1.31 | $1.35 | $1.44 | $1.3 | 6,878 | 5,527 | 80.36% |
05-14-2021 | $1.46 | $1.28 | $1.46 | $1.25 | 46,712 | 33,402 | 71.51% |
05-13-2021 | $1.36 | $1.46 | $1.52 | $1.26 | 98,074 | 81,677 | 83.28% |
05-12-2021 | $1.61 | $1.43 | $1.74 | $1.205 | 252,891 | 161,769 | 63.97% |
05-11-2021 | $1.74 | $1.66 | $1.75 | $1.58 | 51,204 | 26,142 | 51.05% |
05-10-2021 | $1.98 | $1.75 | $1.98 | $1.54 | 88,083 | 57,005 | 64.72% |
05-07-2021 | $2.01 | $2 | $2.14 | $1.98 | 17,092 | 10,478 | 61.3% |
05-06-2021 | $2.08 | $2.0299 | $2.2 | $1.98 | 52,482 | 25,449 | 48.49% |
05-05-2021 | $2.33 | $2.2801 | $2.33 | $2.02 | 1,381 | 908 | 65.75% |
05-04-2021 | $2.3 | $2.15 | $2.3 | $2 | 11,119 | 11,300 | 101.63% |
05-03-2021 | $2.35 | $2.16 | $2.35 | $2.1001 | 44,663 | 28,501 | 63.81% |
04-30-2021 | $2.4 | $2.39 | $2.7 | $2.2499 | 121,185 | 44,168 | 36.45% |
04-29-2021 | $2.64 | $2.75 | $2.75 | $2.4 | 21,746 | 8,976 | 41.28% |
04-28-2021 | $2.57 | $2.7 | $2.78 | $2.52 | 49,020 | 21,985 | 44.85% |
04-27-2021 | $2.6 | $2.7 | $2.74 | $2.48 | 19,977 | 7,902 | 39.56% |
04-26-2021 | $2.5 | $2.69 | $2.79 | $2.32 | 20,906 | 12,296 | 58.82% |
04-23-2021 | $2.5 | $2.5 | $2.5 | $2.4 | 7,729 | 5,895 | 76.27% |
04-22-2021 | $2.35 | $2.47 | $2.5 | $2.3 | 3,074 | 1,822 | 59.27% |
04-21-2021 | $2.35 | $2.5 | $2.5 | $2.2 | 12,335 | 4,597 | 37.27% |
News, Short Squeeze, Breakout and More Instantly...
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis PR Newswire Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK , ...
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery PR Newswire Proposed Schedule III drug classification expected to de-risk Cannasoul's cannabis research and potential regulatory pathways ...